OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
August 05, 2011
Xevo TQD provides ultimate consistency between analyses; instrument to instrument, lab to lab; both the advanced technology of the ACQUITY UPLC System and the robust universal ion source architecture on the Xevo TQD guarantee flexibility and dependability.
August 02, 2011
Are biosimilars the next big thing or just the next big bubble?
A path to personalized medicines creates a new paradigm for development and manufacturing.
July 21, 2011
FDA Approves the Influenza Vaccine Formulation for the 2011-2012 Flu Season.
A bill introduced by Senators Scott Brown (R-MA), Ron Wyden (D-OR), and John McCain (R-AZ) on July 13, 2011, aims to encourage states to reduce Medicaid spending by offering financial incentives to substitute generic drugs for branded ones where possible.
July 02, 2011
The performance of biotechnology venture capital and investment is lackluster at best.
The solid form of an API plays a crucial role in drug quality, and advancing methods for screening, detection, and characterization is key.
Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.
July 01, 2011
A technical leader in solid dosage forms Pfizer CentreSource provides analytical, technical, regulatory, developmental, manufacturing and packaging support that spans the specialized realm of highly potent solid oral dose drug products.
June 16, 2011
Merck and Hanwha Chemical have formed an exclusive global agreement to develop and a commercialize a biosimilar of Enbrel, a drug to treat moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis.